Heterogeneous Treatment Effects: Validate the Average Effect Before Trusting the Subgroups
Anas H. Alzahrani, MD PhD MPH
Department of Preventive Medicine and Public Health
Faculty of Medicine, King Abdulaziz University
The most seductive sentence in modern clinical research is often a subgroup sentence: the average result was neutral, but our model found a group that benefits and another that may be harmed. Sometimes that is a real discovery. Sometimes it is a way for a study that missed the parent effect to keep a more exciting story alive.
Heterogeneous treatment effects are worth studying. Patients are not interchangeable, and a treatment can plausibly work better for some baseline profiles than others. But the order matters. Before asking who benefits?, ask whether the study can recover the effect in the population where the answer is already known. A subgroup analysis is not a repair kit for a broken emulation.
The parent estimate is the first validation gate
Suppose you have electronic health-record data and want to emulate a randomized trial. The target trial gives you a benchmark: eligibility, treatment strategies, time zero, follow-up, outcome, and an average treatment contrast. Your emulation does not need to reproduce the published number exactly. It does need a credible explanation for a meaningful departure.
If the overall emulated effect points in the opposite direction, has a materially different magnitude, or is so imprecise that the benchmark is barely represented, the first job is diagnosis: confounding, treatment-version mismatch, outcome coding, selection, calendar time, adherence, positivity, or random error. The second job is not to search harder for a subgroup.
Decision rule
Treat the average-effect benchmark as a gate, not a decorative citation. If the emulation cannot reproduce the known parent result under a compatible estimand and target population, label downstream HTE findings exploratory until the mismatch is explained.
Why dramatic subgroups can appear after the parent result fails
There are several ways a neutral or discordant average can coexist with apparently spectacular subgroups. Some are real; none are self-authenticating.
Confounding by severity
If treatment assignment is poorly controlled, a model can split patients by prognosis rather than by treatment effect. The subgroup labels may be clinically recognizable while the contrast remains biased.
Threshold hunting
A continuous HTE score can be cut at the point that produces the most attractive separation. The resulting groups are easy to name and hard to validate.
Positivity failure
A subgroup with very little treatment overlap can generate unstable effects. A large point estimate may be a statement about extrapolation, not a treatment that truly helps or harms.
Estimand drift
The benchmark may be an intention-to-treat effect over one follow-up period, while the subgroup analysis silently changes treatment adherence, time horizon, or population. Different questions can produce different answers, but they cannot be compared as if they were the same.
The arithmetic check most subgroup stories skip
On an additive risk-difference scale, the overall effect is the population-weighted average of the subgroup effects. If subgroup A is 40% of the target population and its risk difference is −10 percentage points, while subgroup B is 60% and its risk difference is +1 point, the implied overall effect is −3.4 points. If the paper reports an overall effect of −1 point, something needs explaining: different weights, different estimands, rounding, missing subgroups, modeling contrasts that do not aggregate that way, or an internal error.
This is not a causality test. A biased analysis can be perfectly consistent with itself. It is a coherence check that stops a table of subgroup estimates from floating free of the population estimate that supposedly contains it.
Interactive validation gate
Do the subgroups add back up to the study they came from?
Enter illustrative risk differences in percentage points. The weighted subgroup effects should reconcile with the overall emulated effect. The benchmark is a separate gate: it asks whether the emulation reproduces a known trial result.
Teaching heuristic, not a formal acceptance threshold. Real analyses need compatible estimands, uncertainty intervals, prespecified subgroup definitions, and a causal design that supports the comparison.
A recent RWE example shows the danger
A recent preprint used EHR data to emulate the DAPA-HF trial and then stratified patients using an estimated HTE. The paper reported a non-significant overall emulated contrast alongside strongly divergent beneficial and harmful strata. That pattern may eventually prove informative, but it is exactly the pattern that demands validation rather than applause: when the parent estimate does not recover the known trial signal, subgroup separation could reflect true effect modification, residual bias, or a mixture of both. The abstract itself is a useful reminder that an HTE algorithm can make an observational dataset look more personalized without making its causal assumptions stronger. See Li and colleagues’ preprint.
The right response is not to discard all HTE work. It is to require a sequence: reproduce the average benchmark, audit overlap and covariate balance, pre-specify or transparently discover the effect modifiers, quantify uncertainty, and validate the subgroup rule in a new sample or a held-out time period.
What a defensible HTE analysis reports
| Question | What to look for | Red flag |
|---|---|---|
| Does the emulation recover the parent? | Compatible estimand, target population, uncertainty, and a reasoned benchmark comparison. | A failed average effect is mentioned only in the supplement. |
| Are treatment options available in each subgroup? | Propensity overlap and effective sample size by subgroup. | Extreme weights or a subgroup with almost one treatment arm. |
| Was the subgroup rule protected from optimism? | Pre-specification, sample splitting, bootstrap optimism correction, or external validation. | A threshold chosen after inspecting the most dramatic forest plot. |
| Do the effects transport? | A held-out cohort, later calendar period, or new site with the same treatment rule. | Personalized recommendations from one convenient EHR slice. |
How to review the paper in the right order
- Write down the target trial. Do not compare a subgroup estimate with a benchmark until eligibility, treatment strategies, time zero, follow-up, and outcome align.
- Read the average estimate first. Ask what it says, how uncertain it is, and whether it is compatible with the known randomized result.
- Audit the data support. Check treatment overlap, missingness, censoring, covariate balance, and the number of events inside each subgroup.
- Separate discovery from confirmation. A discovered HTE pattern is a hypothesis until it survives a new sample, time period, site, or trial.
- Demand an action rule. If the paper recommends treating one subgroup differently, ask whether the rule improves decisions, not merely whether the subgroup effects look different.
Where Aqrab fits
Aqrab is useful at the uncomfortable seam between an attractive result and a defensible one. It can pressure-test whether the paper keeps its estimand stable, whether the subgroup claim has an identifiable causal contrast, and whether the validation evidence arrives before the personalized conclusion.
If you are reviewing an HTE paper or writing a target trial emulation, try Aqrab for a methods critique pass, or use the developer workflows to put the checks upstream of publication.
The practical bottom line
Heterogeneity is not a permission slip to skip validation. A subgroup effect is more credible when it is the carefully explained decomposition of a parent result that the design can already reproduce.
So when a paper says the average effect was disappointing but the algorithm found winners and losers, ask the quiet question before the exciting one: does the emulation earn the right to personalize?
Further reading
- Review and benchmark of trial emulation with heterogeneous treatment-effect estimation — why the target-trial framework and HTE machinery must be treated as one design problem.
- Practical guide to estimating and discovering HTEs in epidemiology — a recent methods guide on effect heterogeneity, estimation, and interpretation.
- EHR-derived HTEs for trial protocol optimization — a contemporary example that makes the validation question concrete.
Keep reading
Don't stop at one method.
Good methods judgment comes from contrast. Read the neighboring guides, see where the assumptions diverge, and avoid treating every observational problem like it needs the same hammer.
Causal Readiness: When a Huge Linked Dataset Still Cannot Identify an Effect
A practical guide to causal readiness in linked health and administrative data. Learn why scale and propensity-score overlap are not enough when treatment, need, comparators, or outcomes are poorly measured.
When More Covariates Break Positivity: Representation-Induced Overlap Failure in Clinical Text
A practical guide to representation-induced positivity failure in clinical text. Learn why richer embeddings can encode treatment, shrink common support, and make a causal adjustment less trustworthy.
Predicted Treatment Benefit: When a Risk Model Is Not a Treatment Recommendation
A practical guide to separating predicted outcome risk from predicted treatment benefit. Learn why a high-risk patient is not automatically a high-benefit patient, how risk modeling and effect modeling differ, and what reviewers should demand before trusting a personalized treatment claim.